Bloomberg Teva Pharmaceutical Industries Ltd. plunged to the lowest in more than a decade following a US court ruling that invali-dated four patents on its best-selling multiple sclerosis drug Copaxone. The ruling may open the door to generic competition for a drug that generates a fifth of Teva’s $20 billion in annual sales. The introduction of two Copaxone copycats …

  Bloomberg Microsoft Corp. found ample demand for its $17 billion bond offering, allowing it to cut borrowing rates on its second multibillion note offering in six months. The tech giant received at least twice as many orders as it had bonds to sell, according to people familiar with the matter, who asked not to be named because the deal …

  Bloomberg British households reined in their borrowing in December, casting further doubt over the strength of consumer spending this year. Unsecured lending rose by 1 billion pounds ($1.2 billion), the least since May 2015 and well below the expectations of economists. On an annual basis, credit growth slowed to 10.6 percent from 10.8 percent in November, the Bank of …